In a recent abstract Ma et al. presented data on 93 ER-positive and HER2-negative breast cancer patients who participated in the ALTERNATE trial which suggested a higher pCR rate of 16.7% in patients with non-luminal cancers compared to 4.0% in patients with Luminal A or Luminal B subtypes22. Here, ERBB2 is linked to cancer.